1 min read
Add as a preferred source on GoogleDr. Reddy’s Targets November Relaunch of Generic Semaglutide
Validation results remain pending; the company reiterated a target of 6 million to 7 million devices for FY27.
Dr. Reddy’s Laboratories Limited is targeting a generic semaglutide relaunch by November 2026, while retaining a goal of 6 million to 7 million devices for FY27, pending validation results.
CEO Erez Israeli said he was confident the validation would succeed. The results were still pending during the company’s Oct. 23 earnings call.
Dr. Reddy’s second quarter generated $905 million in revenue and diluted EPS of $0.12, figures also outlined in an earlier results story.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.